Altimmune (ALT) AI Stock Analysis

• Market Cap: $462.31M
• Dividend Yield: N/A
• Average Volume (3M): 2.37M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.40
• Revenue Growth: -95.12%
• EPS Growth: 21.09%
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 81,106,970
• 10 Day Avg. Volume: 2,932,967
• 30 Day Avg. Volume: 2,374,621
• PEG Ratio: -0.29
• Price to Book (P/B): 3.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $21.86
• Price Target Upside: 291.76% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

Altimmune's overall score reflects a mix of financial challenges and optimistic future prospects. The strong balance sheet and strategic financial moves provide stability, while upcoming clinical trial results and expansions into new therapeutic areas offer potential growth. However, ongoing profitability and cash flow issues, along with a negative valuation, weigh down the score.

Positive Factors

Clinical Trials

The highly-anticipated Phase 2b trial (IMPACT) readout is a key near-term catalyst for investors.

Financial Position

Altimmune's strong financial position ensures that the IMPACT readout and subsequent FDA interactions are fully funded.

Product Differentiation

Pemvidutide's dual mechanism of action could have beneficial impacts on both weight loss and liver health, which is supported by clinical results.

Negative Factors

Market Competition

Pemvidutide could be the first incretin-based therapy to achieve fibrosis improvement at 24 weeks, setting it apart from both GLP-1 monotherapies and other liver-directed agents.

Valuation

ALT currently seems undervalued trading at a discount to current Phase 3 MASH companies, presenting a significant opportunity to catch up in valuation.

Altimmune Business Overview & Revenue Model

Company Description

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

How the Company Makes Money

Altimmune generates revenue primarily through research and development collaborations, government contracts, and grants. The company partners with various organizations to develop and commercialize its product candidates. These partnerships often include milestone payments and royalties based on sales of successfully developed products. Additionally, Altimmune may receive funding from governmental and non-governmental agencies to support its R&D efforts in areas of public health interest.

Altimmune Financial Statement Overview

Summary

Altimmune faces significant challenges in achieving profitability and positive cash flow, as indicated by negative margins and cash flow metrics. However, the company maintains a strong balance sheet with low leverage, providing a cushion for future growth opportunities.

Income Statement

Altimmune has shown inconsistent revenue figures over the years, with a significant drop in the most recent period. Gross profit margins have been volatile, and the company has consistently posted negative net income, leading to negative net profit margins. The EBIT and EBITDA margins are also negative, indicating operational challenges in achieving profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 88.65% in the latest period, reflecting a solid balance sheet with minimal debt. The debt-to-equity ratio is favorable, indicating low financial leverage. However, the persistent net income losses have impacted the return on equity, which remains negative.

Cash Flow

Altimmune has experienced negative free cash flow, indicating challenges in generating cash from operations. The operating cash flow to net income ratio is negative, as is the free cash flow to net income ratio, reflecting the company's difficulties in translating earnings into cash flow.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
20.00K	426.00K	-68.00K	4.41M	8.19M
	Gross Profit
20.00K	-51.00K	-136.00K	3.86M	-25.32M
	EBIT
-103.17M	-95.93M	-87.74M	-96.91M	-54.80M
	EBITDA
-94.81M	-87.94M	-84.40M	-96.53M	-54.15M
	Net Income Common Stockholders
-95.06M	-88.45M	-84.71M	-96.17M	-49.04M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
131.89M	197.81M	184.88M	190.30M	215.92M
	Total Assets
139.31M	210.64M	206.93M	218.86M	245.12M
	Total Debt
1.68M	671.00K	1.12M	1.54M	1.82M
	Net Debt
-35.24M	-134.45M	-109.97M	-188.77M	-114.09M
	Total Liabilities
15.80M	16.54M	21.64M	19.73M	19.24M
	Stockholders Equity
123.51M	194.10M	185.29M	199.13M	225.88M
Cash Flow		Free Cash Flow
-79.85M	-75.86M	-62.71M	-90.55M	-34.78M
	Operating Cash Flow
-79.85M	-75.81M	-62.59M	-78.24M	-34.44M
	Investing Cash Flow
-28.39M	13.73M	-73.40M	87.52M	-72.09M
	Financing Cash Flow
10.04M	86.11M	56.78M	65.10M	213.49M

Altimmune Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.58
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALT, the sentiment is Neutral. The current price of 5.58 is above the 20-day moving average (MA) of 5.36, above the 50-day MA of 5.19, and below the 200-day MA of 6.60, indicating a neutral trend. The MACD of 0.19 indicates Negative momentum. The RSI at 53.84 is Neutral, neither overbought nor oversold. The STOCH value of 62.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ALT.

Altimmune Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	66 Neutral	$490.83M	12.24	20.50%	―	2333.50%	―
Sector *	52 Neutral	$5.04B	3.15	-44.58%	2.85%	16.08%	-0.27%
ALT	52 Neutral	$462.31M	―	-57.28%	―	-95.12%	21.09%
IVA	50 Neutral	$488.85M	―	344.74%	―	-47.32%	-26.67%
AUTL	45 Neutral	$324.69M	―	-49.97%	―	-14.16%	25.80%
ORIC	43 Neutral	$345.84M	―	-48.45%	―	―	7.15%
SANA	33 Underperform	$401.49M	―	-71.44%	―	―	19.94%

Altimmune Corporate Events

Altimmune Secures $100 Million Credit Facility

On May 13, 2025, Altimmune entered into a Loan and Security Agreement with Hercules Capital, securing a $100 million credit facility to enhance its financial flexibility and support the development of its lead therapeutic candidate, pemvidutide. The company announced its first quarter 2025 financial results, reporting cash and short-term investments of $150 million as of March 31, 2025. Altimmune anticipates significant milestones in 2025, including top-line data from the IMPACT Phase 2b trial of pemvidutide in MASH, and the initiation of Phase 2 trials for AUD and ALD. These developments are expected to strengthen Altimmune’s position in the biopharmaceutical industry, particularly in addressing unmet medical needs in liver and cardiometabolic diseases.

The most recent analyst rating on (ALT) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.

Spark’s Take on ALT Stock

According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.

Altimmune’s strong balance sheet and promising clinical pipeline are positive, but challenges remain with profitability and cash flow. Technical indicators are neutral, while the earnings call provides some optimism for future growth.

To see Spark’s full report on ALT stock, click here.

Altimmune Reports 2024 Financial Results and R&D Progress

Altimmune announced its financial results for the fourth quarter and full year of 2024, highlighting significant progress in the development of pemvidutide. The company completed enrollment for the Phase 2b IMPACT trial in MASH and expects to report top-line data in Q2 2025. Additionally, Altimmune received FDA clearance for investigational new drug applications in two more indications, with Phase 2 trials slated for mid-2025. The company also strengthened its board with two new pharmaceutical industry veterans and plans to host a virtual R&D Day on March 13, 2025, to discuss further developments.

Altimmune Expands Board Amid Late-Stage Drug Development

On February 24, 2025, Altimmune, Inc. expanded its Board of Directors by appointing Teri Lawver and Jerome Durso, both seasoned executives in the biopharmaceutical industry. This strategic move comes as the company progresses into late-stage clinical development of pemvidutide, a promising treatment for liver and metabolic diseases. Lawver and Durso bring extensive experience in commercialization and corporate strategy, which is expected to bolster Altimmune’s efforts in transitioning to a pre-commercial-stage organization and advancing its strategic vision.